MURA (Mural Oncology) Net Margin % : 0.00% (As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Mural Oncology Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Mural Oncology's Net Income for the three months ended in Dec. 2024 was $-34.27 Mil. Mural Oncology's Revenue for the three months ended in Dec. 2024 was $0.00 Mil. Therefore, Mural Oncology's net margin for the quarter that ended in Dec. 2024 was 0.00%.

The historical rank and industry rank for Mural Oncology's Net Margin % or its related term are showing as below:

MURA's Net Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -122.46
* Ranked among companies with meaningful Net Margin % only.

Mural Oncology Net Margin % Historical Data

The historical data trend for Mural Oncology's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mural Oncology Net Margin % Chart

Mural Oncology Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Net Margin %

Mural Oncology Quarterly Data
	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Net Margin %	Get a 7-Day Free Trial							-	-	-	-	-

Competitive Comparison of Mural Oncology's Net Margin %

For the Biotechnology subindustry, Mural Oncology's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mural Oncology's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mural Oncology's Net Margin % distribution charts can be found below:

* The bar in red indicates where Mural Oncology's Net Margin % falls into.

Save Embed

;

Save Embed

;

Mural Oncology Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Mural Oncology's Net Margin for the fiscal year that ended in Dec. 2024 is calculated as

Net Margin	=	Net Income (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	-128.514	/	0
	=	%

Mural Oncology's Net Margin for the quarter that ended in Dec. 2024 is calculated as

Net Margin	=	Net Income (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	-34.274	/	0
	=	%

Mural Oncology (NAS:MURA) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Mural Oncology Net Margin % Related Terms

Thank you for viewing the detailed overview of Mural Oncology's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Mural Oncology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mural Oncology PLC (NAS:MURA) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

10 Earlsfort Terrace, Dublin 2, Dublin, IRL, D02 T380

Website

https://www.muraloncology.com

Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.